Tags : Lexent

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

Tuba Khan June 22, 2020

1. Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, […]readmore

M&A

Foundation Medicine Acquires Lexent to Expand its Liquid Biopsy Platforms

Tuba Khan June 15, 2020

Shots: Foundation Medicine acquires Lexent to accelerate the Foundation’s R&D strategy and expand its existing liquid biopsy platforms to advance cancer care for patients. The acquisition will boost Foundation Medicine’s […]readmore

Tags : Lexent

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

Foundation Medicine Acquires Lexent to Expand its Liquid Biopsy Platforms

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Lexent

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

Foundation Medicine Acquires Lexent to Expand its Liquid Biopsy Platforms

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company